Last reviewed · How we verify
GnRH agonist trigger
GnRH agonist trigger induces a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to trigger final oocyte maturation and ovulation in assisted reproductive technology cycles.
GnRH agonist trigger induces a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to trigger final oocyte maturation and ovulation in assisted reproductive technology cycles. Used for Final oocyte maturation trigger in assisted reproductive technology (ART) cycles, Ovulation induction in controlled ovarian hyperstimulation protocols.
At a glance
| Generic name | GnRH agonist trigger |
|---|---|
| Also known as | Oovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG. |
| Sponsor | Rambam Health Care Campus |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
GnRH agonists bind to GnRH receptors on pituitary gonadotroph cells, causing an initial surge in gonadotropin release. This LH surge triggers the resumption of meiosis I in oocytes and weakening of follicular attachments, leading to ovulation. In ART protocols, the agonist is used after pituitary downregulation to provide a physiologic trigger for final egg maturation and retrieval timing.
Approved indications
- Final oocyte maturation trigger in assisted reproductive technology (ART) cycles
- Ovulation induction in controlled ovarian hyperstimulation protocols
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal discomfort
Key clinical trials
- Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer (PHASE4)
- Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
- IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women (NA)
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality (NA)
- Aurora Test for ART Donor Patients (AURORA-Donor)
- Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer (PHASE3)
- Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRH agonist trigger CI brief — competitive landscape report
- GnRH agonist trigger updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI